The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 21, 2014
Filed:
Sep. 27, 2011
Naoki Nishiguchi, Ibaraki, JP;
Akiyoshi Hirayama, Ibaraki, JP;
Masahiro Furutani, Ibaraki, JP;
Tatsuo Shimizu, Osaka, JP;
Kiyoshi Takayama, Hokkaido, JP;
Tomoko Shimizu, Hokkaido, JP;
Kazuya Suzuki, Tokyo, JP;
Naoki Nishiguchi, Ibaraki, JP;
Akiyoshi Hirayama, Ibaraki, JP;
Masahiro Furutani, Ibaraki, JP;
Tatsuo Shimizu, Osaka, JP;
Kiyoshi Takayama, Hokkaido, JP;
Tomoko Shimizu, Hokkaido, JP;
Kazuya Suzuki, Tokyo, JP;
Sekisui Chemical Co., Ltd., Osaka, JP;
NE Health Laboratory Co., Ltd., Hokkaido, JP;
Abstract
The present invention is novel anti-human-CC-motif-receptor-7 (anti-human-CCR7) antibodies useful for treating tissue fibrosis or cancer, and pharmaceutical compositions containing the anti-human-CCR7 antibodies. The invention includes an anti-human-CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77. The invention also includes an anti-human-CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.